News
Meet us at ELRIG Drug Discovery 2023 Event!
ELRIG Drug Discovery 2023 congress will take place in Liverpool next week (October, 18 & 19th 2023). Our project leader Dr. Véronique De Conto will have the pleasure for presenting a poster about High Content Screening in 3D models including the tumoral Extracellular Matrix. Abstract: In oncology, 97% of drug Read more…
Biomimesys
HCS Pharma is delighted to help Vidac Pharma in the fight against cancer
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Pharma and HCS Pharma announce cooperative agreement on acceleration of pre-clinical assays for Vidac Pharma Read more…
Biomimesys
Collaboration with CANTHER about breast cancer metastasis presented @EACR2023
Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, during which Julien could discuss with cancer researchers from all around the world. His poster Read more…
News
Avancées prometteuses dans la lutte contre le cancer : les projets innovants de HCS Pharma
Chez HCS Pharma, nous sommes ravis de partager avec vous les avancées significatives que nous avons réalisées dans nos projets de recherche et développement. Avant de commencer, nous tenons à remercier “La Gazette du Laboratoire” pour leur soutien continu et leur couverture détaillée de nos efforts. Notre entreprise, basée à Read more…
News
Business trip in Asia: what makes China different !
After Japan, the business trip has been been continued in Taïwan for several days! As a scientist, I was really happy to see such open-mind spirit when I present BIOMIMESYS technology and how this kind of technology will change the drug discovery process and help the cell therapy/regenerative medicine in Read more…
Biomimesys
Back from ATAE conference by Adebiotech
Last week, we had the pleasure to participate in the conference about Alternatives to Animal Experimentation which was held last week in Biocitech park, Romainville, France. It was organized by Adebiotech think tank, and gathered researchers from private companies and academia, and also people from organizations like FC3R and PETA Read more…
Biomimesys
Advantages of 3D Cell Culture in Immuno-Oncology
In recent years, 3D cell culture has emerged as a promising approach to studying the immune system and its interactions with cancer cells. Indeed, 3D cell culture mimics better the natural architecture of tissues and provides a more physiologically relevant models for drug discovery. One of the major advantages of Read more…
biomimesys_oncology
The importance of 3D culture for the study of driver oncogenes
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to the transformation of a normal cell into a cancerous cell by activating signaling pathways involved Read more…
Biomimesys
Meet HCS PHARMA at Forum Labo!
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Meryl Roudaut, our Project leader in metabolic tissues, and our Project director Elodie VANDENHAUTE will Read more…
Biomimesys
HCS Pharma’s series of webinars
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more about BIOMIMESYS®, an amazing and disruptive technology that reproduces all aspects of the microenvironment (matrix Read more…
Biomimesys
It is Blue March for colon cancer testing!
Why is testing important? One million cases of colon cancer are diagnosed each year around the world. Colorectal cancer develops slowly. The tumor, called polyp, appears on the inner wall of the colon and rectum. The evolution of a polyp into cancer can last about ten years. The test can Read more…
Our news
HCS Pharma will be present at next ELRIG event “Research and Innovation 2023 – Accelerating future DD” in Cambridge on March 29 and 30th
We are pleased to participate in ELRIG event about Research an Innovation 2023 – Accelerating future drug discovery” in Cambridge on March 29 and 30th 2023. Veronique De Conto, our project leader in in vitro Pharmacology, is very happy to meet with you and to present you our disruptive technology Read more…
Biomimesys
Three projects for HCS Pharma with ONCOLille Institute thanks to Plan France Relance and Région Hauts-de-France
The beginning of 2023 is tremendous for HCS Pharma in terms of new oncology-related collaborative R&D projects, with three of them accepted and granted by ANR (Agence Nationale pour la Recherche) through the Plan France Relance, and by the Région Hauts-de-France through STIMuLE plan. It has been announced in a Read more…
Biomimesys
Poster : BIOMIMESYS®, a ready-to-use ECM for Relevant Phenotypic Screening
Poster presented during the SLAS event in San Diego on the 27th and 28th of February 2023. Title: BIOMIMESYS® Hydroscaffold, a ready-to-use organ-specific Extracellular Matrix for Relevant Phenotypic Screening Dr. Nathalie Maubon*, Dr. Véronique De Conto, Dr. Méryl Roudaut, Dr Alejandra Mogrovejo – Valdivia, Julien Leriche, Vaihere Cheung and Dr Read more…
Biomimesys
What are the in vitro alternatives to animal testing in breast cancer research?
2.2 million cases of breast cancer were identified in 2020 by the WHO. This cancer is the first cause of cancer in women. It develops in the glandular lobes or milk ducts. Five subtypes of breast cancer have been defined but their origin is not yet determined. The heterogeneity of Read more…
News
We welcome Nathan for a PhD thesis on breast cancer metastasis
After obtaining this Master’s degree in Biology and Health Science at Lille University in 2022, Nathan Laneret has just begun a PhD thesis under the supervision of Pr. RA Toillon and Dr. Nathalie Maubon thanks to ANRT fundings (CIFRE). Through this collaboration between the Cellular Plasticity and Cancer team from Canther Lab Read more…
Biomimesys
Feedback to the first OncoLille Days Congress
The first edition of OncoLille Days congress took place from November 2th to 4th, 2022 in Lille. All 3 days were very rich in interesting presentations about interdisciplinary research in oncology, including biology, mathematics, human sciences, etc. Our project leader Véronique De Conto was pleased to present her poster about Read more…
Biomimesys
De retour de l’INEM sur le stand Dominique Dutscher – HCS Pharma
Nous avons eu le plaisir d’être invités par notre distributeur Dutscher, et en particulier par Romain Guegan, à présenter lors de la journée Necker-Imagine organisée à l’INEM (Institut Necker Enfants Malades) le 3 novembre dernier. Elodie a eu l’occasion de présenter aux chercheurs présents notre technologie BIOMIMESYS® pour une culture Read more…
Biomimesys
Poster – Including the matricial tumoral microenvironment in 3D in vitro models by using a Hyaluronic-Acid-based hydroscaffold™
Abstract: In oncology, 97% of drug candidates fail in clinical trials. This highlights a lack of relevance of preclinical models used upstream. Indeed, human in vitro models don’t consider the Tumoral Extracellular Matrix (TECM). However, more and more studies demonstrate that ECM composition and stiffness are modified in tumors and Read more…
Biomimesys
Meet us in OncoLille Days 2022 where we present a poster about matricial tumoral microenvironment in 3D in vitro models
We are pleased to participate in the first OncoLille Days congress from November 2th to 4th, 2022. Inaugurated on October 12th, 2022, OncoLille Institute aims at developing an interdisciplinary research in oncology, including biology, physics, microtechnologies, chemistry, mathematics, bioinformatics, statisitcs, health technologies and social and human sciences. HCS Pharma collaborates Read more…
Biomimesys
Discover BIOMIMESYS® uses with Pr Robert-Alain Toillon (Canther – OncoLile)
We are very pleased to talk with Pr Robert-Alain Toillon from University of Lille about his uses of BIOMIMESYS® technology in oncology and more specificaly on breast cancer. English is below Je m’appelle Robert-Alain Toillon je travaille au laboratoire Canther dans l’institut OncoLille sur le cancer du sein et plus Read more…